Skip to main content
Alyssa Johnsen, MD, Internal Medicine, Cambridge, MA

AlyssaJohnsenMD

Internal Medicine • Cambridge, MA

Rheumatology

Physician

Join to view full profile

Are you Dr. Johnsen?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 37 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Alyssa Johnsen, MD is an internist in Cambridge, Massachusetts. She is currently licensed to practice medicine in Pennsylvania.

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Rheumatology, 2003 - 2007
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 2001 - 2003
  • Case Western Reserve University School of Medicine
    Case Western Reserve University School of MedicineClass of 2001

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2009 - 2016

Awards, Honors, & Recognition

  • Fellow American College of Rheumatology

Publications & Presentations

PubMed

Press Mentions

  • New Phase 3 First-in-Class TREMFYA® (Guselkumab) Data Show Durability of Joint Efficacy, Including Low Rates of Structural Damage Progression, and a Demonstrated Safety Profile in Adults with Active Psoriatic Arthritis (PsA)
    New Phase 3 First-in-Class TREMFYA® (Guselkumab) Data Show Durability of Joint Efficacy, Including Low Rates of Structural Damage Progression, and a Demonstrated Safety Profile in Adults with Active Psoriatic Arthritis (PsA)November 1st, 2021
  • New Comprehensive Phase 3 Data Show First-in-Class TREMFYA® (Guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
    New Comprehensive Phase 3 Data Show First-in-Class TREMFYA® (Guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two YearsNovember 1st, 2021
  • (Guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
    (Guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)June 2nd, 2021
  • Join now to see all

Dr. Alyssa Johnsen, Dr. Alyssa Johnsen, MD, Dr. A Johnsen